Prima gets go ahead for ovarian cancer vaccine trial in US
Wednesday, 02 September, 2009
Prima BioMed is a step closer to commercialisation of its ovarian cancer vaccine, CVac, with the US Food and Drug Administration giving the go ahead on a Phase IIb trial.
This follows positive results from a Phase IIa trial conducted in Australia in 2006, with the final results announced in March 2007.
The new trial will be conducted at the Fred Hutchinson Cancer Centre in Seattle in the US and will involve 60 patients. It will seek to assess the efficacy of CVac to stimulate the patient's own immune system to target and destroy tumours.
CVac is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer.
Prima BioMed's (ASX:PRR) share price lifted 10% to $0.11 following the announcement.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
